Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Clinical trial NCT04739059 · COMPLETED

Trial details

NCT number: NCT04739059
Sponsor: CSL Behring
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hereditary Angioedema

Start date: 2021-03-29
Primary completion: 2025-11-21
Enrollment: 171

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.